Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren vs ARB for Microalbuminuria in Hypertensive T2D Patients (SMART2)
NCT01461499Phase 4Completed
- Sponsor
- Shiga University
- Start
- Oct 2011
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aliskiren in hypertension (HTN) and diabetic nephropathy (DN) (2 arms), sponsored by Shiga University. Primary endpoint: Reduction in Albuminuria at 24 weeks. Started Oct 2011; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01461499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01461499.